Please use this identifier to cite or link to this item:
Title: Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial
Austin Authors: Nichol A, A;French, C;Little, L;Haddad, S;Presneill, J;Arabi, Y;Bailey, M;Cooper, DJ;Duranteau, J;Huet, O;Mak, A;McArthur, C;Pettila, V;Vallance, S;Varma, D;Wills, J;Bellomo, Rinaldo ;EPO-TBI Investigators;ANZICS Clinical Trials Group.;Skrifvars, M
Affiliation: Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia
Alfred Hospital, Melbourne, VIC, Australia
School of Medicine and Medical Sciences, University College Dublin, Dublin Ireland
St Vincent's University Hospital, Dublin, Ireland
University of Melbourne, Melbourne, VIC, Australia
Western Health, Melbourne, VIC, Australia
King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia
University of Queensland, Brisbane, QLD, Australia
Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
King Saud Bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
Département d'Anesthésie-Réanimation, Hôpital de Bicêtre, Assistance Publique des Hopitaux de Paris, Hôpitaux Universitaires Paris-Sud, Université Paris-Sud, Paris, France
Department of Anaesthesiology and Intensive Care Medicine, CHU La Cavale Blanche, Brest, France
Auckland City Hospital, Auckland, New Zealand
University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Austin Hospital, Melbourne, VIC, Australia
Issue Date: 2015 2015-10-06
Publication information: Lancet. 2015 Oct 6. [Epub ahead of print]
Abstract: Erythropoietin might have neurocytoprotective effects. In this trial, we studied its effect on neurological recovery, mortality, and venous thrombotic events in patients with traumatic brain injury. METHODS: Erythropoietin in Traumatic Brain Injury (EPO-TBI) was a double-blind, placebo-controlled trial undertaken in 29 centres (all university-affiliated teaching hospitals) in seven countries (Australia, New Zealand, France, Germany, Finland, Ireland, and Saudi Arabia). Within 24 h of brain injury, 606 patients were randomly assigned by a concealed web-based computer-generated randomisation schedule to erythropoietin (40 000 units subcutaneously) or placebo (0·9% sodium chloride subcutaneously) once per week for a maximum of three doses. Randomisation was stratified by severity of traumatic brain injury (moderate vs severe) and participating site. With the exception of designated site pharmacists, the site dosing nurses at all sites, and the pharmacists at the central pharmacy in France, all study personnel, patients, and patients' relatives were masked to treatment assignment. The primary outcome, assessed at 6 months by modified intention-to-treat analysis, was improvement in the patients' neurological status, summarised as a reduction in the proportion of patients with an Extended Glasgow Outcome Scale (GOS-E) of 1-4 (death, vegetative state, and severe disability). Two equally spaced preplanned interim analyses were done (after 202 and 404 participants were enrolled). This study is registered with, number NCT00987454. FINDINGS: Between May 3, 2010, and Nov 1, 2014, 606 patients were enrolled and randomly assigned to erythropoietin (n=308) or placebo (n=298). Ten of these patients (six in the erythropoietin group and four in the placebo group) were lost to follow up at 6 months; therefore, data for the primary outcome analysis was available for 596 patients (302 in the erythropoietin group and 294 in the placebo group). Compared with placebo, erythropoietin did not reduce the proportion of patients with a GOS-E level of 1-4 (134 [44%] of 302 patients in the erythropoietin group vs 132 [45%] of 294 in the placebo group; relative risk [RR] 0·99 [95% CI 0·83-1·18], p=0·90). In terms of safety, erythropoietin did not significantly affect 6-month mortality versus placebo (32 [11%] of 305 patients had died at 6 months in the erythropoietin group vs 46 [16%] of 297 [16%] in the placebo group; RR 0·68 [95% CI 0·44-1·03], p=0·07) or increase the occurrence of deep venous thrombosis of the lower limbs (48 [16%] of 305 vs 54 [18%] of 298; RR 0·87 [95% CI 0·61-1·24], p=0·44). INTERPRETATION: Following moderate or severe traumatic brain injury, erythropoietin did not reduce the number of patients with severe neurological dysfunction (GOS-E level 1-4) or increase the incidence of deep venous thrombosis of the lower limbs. The effect of erythropoietin on mortality remains uncertain.
DOI: 10.1016/S0140-6736(15)00386-4
Journal: Lancet
PubMed URL:
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.